OBJECTIVE: To investigate the prognostic value of the Gleason score in prostate cancer. PATIENTS AND METHODS: A consecutive series of 305 men with prostate cancer diagnosed at transurethral resection (1975-1990) and with no curative treatment was analysed. There was no assessment of prostate-specific antigen level during this period. The mean (range) age at diagnosis was 73.7 (52-95) years and the mean follow-up was 6.4 (0-22) years. The influence of Gleason score and the percentage of the specimen area with tumour (% cancer) on disease-specific survival were assessed using Kaplan-Meier analyses. RESULTS: Of 305 cancers, 22% had a Gleason score of 4-5, 29% of 6, 18% of 7 and 32% of 8-10. At the follow-up, 89% of the men had died, of whom 42% had died from prostate cancer. The disease-specific 10-year survival was 56%. The disease-specific mean survival (DSMS) for Gleason score 4-5, 6, 7 and 8-10 was 20, 16, 10 and 5 years, respectively (P < 0.001). The DSMS did not differ significantly between Gleason 4 and 5 or between 8-10. There was a trend towards shorter survival for Gleason 4 + 3=7 (DSMS 9 years) than GS 3 + 4=7 (DSMS 13 years; P = 0.16). Gleason score and % cancer were independent predictors of DSMS (P < 0.001). CONCLUSION: The long-term prognosis of prostate cancer on deferred treatment is predicted well by the Gleason score. Four prognostic categories of prostate cancer are suggested, i.e. Gleason score 4-5, 6, 7 and 8-10.
OBJECTIVE: To investigate the prognostic value of the Gleason score in prostate cancer. PATIENTS AND METHODS: A consecutive series of 305 men with prostate cancer diagnosed at transurethral resection (1975-1990) and with no curative treatment was analysed. There was no assessment of prostate-specific antigen level during this period. The mean (range) age at diagnosis was 73.7 (52-95) years and the mean follow-up was 6.4 (0-22) years. The influence of Gleason score and the percentage of the specimen area with tumour (% cancer) on disease-specific survival were assessed using Kaplan-Meier analyses. RESULTS: Of 305 cancers, 22% had a Gleason score of 4-5, 29% of 6, 18% of 7 and 32% of 8-10. At the follow-up, 89% of the men had died, of whom 42% had died from prostate cancer. The disease-specific 10-year survival was 56%. The disease-specific mean survival (DSMS) for Gleason score 4-5, 6, 7 and 8-10 was 20, 16, 10 and 5 years, respectively (P < 0.001). The DSMS did not differ significantly between Gleason 4 and 5 or between 8-10. There was a trend towards shorter survival for Gleason 4 + 3=7 (DSMS 9 years) than GS 3 + 4=7 (DSMS 13 years; P = 0.16). Gleason score and % cancer were independent predictors of DSMS (P < 0.001). CONCLUSION: The long-term prognosis of prostate cancer on deferred treatment is predicted well by the Gleason score. Four prognostic categories of prostate cancer are suggested, i.e. Gleason score 4-5, 6, 7 and 8-10.
Authors: Ramzi Rajab; Gabrielle Fisher; Michael W Kattan; Christopher S Foster; Henrik Møller; Tim Oliver; Victor Reuter; Peter T Scardino; Jack Cuzick; Daniel M Berney Journal: Mod Pathol Date: 2010-09-10 Impact factor: 7.842
Authors: Daniel N Costa; Qi Cai; Yin Xi; Debora Z Recchimuzzi; Naveen Subramanian; Aditya Bagrodia; Neil M Rofsky; Claus G Roehrborn; Brad Hornberger; Rajal B Shah; Kenneth Goldberg; Alberto Diaz de Leon; Ivan Pedrosa Journal: Radiol Imaging Cancer Date: 2021-03-05
Authors: Ernest J Feleppa; Christopher R Porter; Jeffrey Ketterling; Paul Lee; Shreedevi Dasgupta; Stella Urban; Andrew Kalisz Journal: Ultrason Imaging Date: 2004-07 Impact factor: 1.578
Authors: Sung Yoon Park; Young Taik Oh; Dae Chul Jung; Nam Hoon Cho; Young Deuk Choi; Koon Ho Rha; Sung Joon Hong Journal: Eur Radiol Date: 2015-11-11 Impact factor: 5.315
Authors: Tanja Spethmann; Lukas Clemens Böckelmann; Vera Labitzky; Ann-Kristin Ahlers; Jennifer Schröder-Schwarz; Sarah Bonk; Ronald Simon; Guido Sauter; Hartwig Huland; Robert Kypta; Udo Schumacher; Tobias Lange Journal: Mol Oncol Date: 2021-02-17 Impact factor: 6.603